1-8 of 8
Shigeki Yagyu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Selective JAK2 Pathway Inhibitor, CHZ868, Ameriorates Anti-Leukemic Functionaliry in CD19 CAR-T Cells

Kohei Mitsuno, Masaya Suematsu, Azusa Mayumi, Hideki Yoshida, Shinya Osone, Toshihiko Imamura, Yozo Nakazawa, Shigeki Yagyu, Tomoko Iehara
Journal: Blood
Blood (2024) 144 (Supplement 1): 4784.
https://doi.org/10.1182/blood-2024-199010
Published: 2024
Journal Articles

A Phase I/II Clinical Trial of Piggybac -Modified GMR CAR-T Cell Therapy for CD116 Positive Relapsed/Refractory Myeloid Malignancies

Shoji Saito, Miyuki Tanaka, Aiko Hasegawa, Yoichi Inada, Hirokazu Morokawa, Yoko Usami, Shunsuke Kojima, Ryu Yanagisawa, Chinatsu Miyazawa, Keiko Ito, Hitoshi Sakai, Hideyuki Nakazawa, Haruko Tashiro, Shigeki Yagyu, Yozo Nakazawa
Journal: Blood
Blood (2021) 138 (Supplement 1): 4813.
https://doi.org/10.1182/blood-2021-149089
Published: 2021
Journal Articles

Piggybac Transposon Mediated CD19 CAR-T Cells Derived from CD45RA-Positive PBMCs Possess Potent and Sustained Antileukemic Function

Masaya Suematsu, Shigeki Yagyu, Nobuyoshi Nagao, Susumu Kubota, Yuto Shimizu, Miyuki Tanaka, Yozo Nakazawa, Toshihiko Imamura
Journal: Blood
Blood (2021) 138 (Supplement 1): 2807.
https://doi.org/10.1182/blood-2021-145863
Published: 2021
Journal Articles

Mutated GM-CSF-Based CAR T-Cells Targeting CD116/CD131 Complexes Exhibit Enhanced Anti-Tumor Effects Against Acute Myeloid Leukemia

Shoji Saito, MD PhD, Aiko Hasegawa, PhD, Mika Nagai, Yoichi Inada, Hirokazu Morokawa, MD, Ikumi Nakashima, Daisuke Morita, MD, PhD, Yuichiro Ide, Kazuyuki Matsuda, PhD, Haruko Tashiro, MD, Shigeki Yagyu, MD PhD, Miyuki Tanaka, MD PhD, Yozo Nakazawa, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-134395
Published: 2020
Journal Articles

Tumor-Tropic Liposome-Mediated Therapeutic Delivery of mRNA for T Cell Malignancies

Shoji Saito, MD PhD, Ikumi Nakashima, Aiko Hasegawa, PhD, Eiichi Akahoshi, Mitsuko Ishihara-Sugano, Shigeki Yagyu, MD PhD, Yozo Nakazawa, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-139020
Published: 2020
Journal Articles

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

Soranobu Ninomiya, Neeharika Narala, Leslie Huye, Shigeki Yagyu, Barbara Savoldo, Gianpietro Dotti, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Carlos A. Ramos
Journal: Blood
Blood (2015) 125 (25): 3905–3916.
https://doi.org/10.1182/blood-2015-01-621474
Published: 2015
Includes: Supplemental data
Journal Articles

Specific MLL Fusion Partners Affect the Sensitivity of Human and Murine Leukemic Cell Lines to Demethylating Agents

Atsushi Fujiki, MD, Toshihiko Imamura, MD, PhD, Hideki Yoshida, MD, Yoshifumi Hirashima, MD, Mitsuru Miyachi, MD, PhD, Shigeki Yagyu, MD, PhD, Kanji Sugita, MD, PhD, Hajime Hosoi, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2158.
https://doi.org/10.1182/blood.V116.21.2158.2158
Published: 2010
Journal Articles

Monocytic Differentiation of Myeloid Leukemia Cell Lines Induced by ATRA and 5-Aza-2'-Deoxycitidine.

Atsushi Fujiki, MD, Toshihiko Imamura, Yoshifumi Hirashima, Mitsuru Miyachi, Shigeki Yagyu, Takuya Nakatani, Kanji Sugita, Hajime Hosoi
Journal: Blood
Blood (2009) 114 (22): 3111.
https://doi.org/10.1182/blood.V114.22.3111.3111
Published: 2009